PFE Stock Recent News

Holding dividend stocks remains one of the most effective long-term strategies, with companies that pay a regular dividend often being profitable and well-positioned for future growth, even during economic downturns.

Jeff J Mitchell / Getty Images News via Getty Images Pfizer (PFE) Price Prediction 2025–2030 The current consensus one-year price target for Pfizer, according to analysts, is $27.63, which represents 17.42% potential upside over the next 12 months based on PFE's current share price.

High-yield stocks are often riddled with flaws. However, there are some high-yield stocks available today that check all of my boxes. I share some of my top high-yield picks of the moment.

PHILADELPHIA , June 3, 2025 /PRNewswire/ --  Berger Montague advises shareholders of Pfizer Inc. ("Pfizer" or the "Company") (NYSE: PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera.  Shareholders of PFIZER may learn more about this investigation by contacting Berger Montague: Radha Raghavan at rraghavan@bm.net  or (332) 271-8908, or Andrew Abramowitz at aabramowitz@bm.net  or (215) 875-3015 or visit: https://investigations.bergermontague.com/pfizer/   Berger Montague's investigation is focused on whether Pfizer's Board of Directors breached its fiduciary duties in the manner in which it oversaw the Company's marketing and sale of Depo-Provera, an injectable used for contraception or to treat endometriosis, as well as other indications.

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

PFE's meltdown has already triggered the richer forward dividend yields, made secure by the growing cash flow and the ongoing cost optimizations. The same has been observed in the FQ1'25 adj EPS outperformance, reiterated FY2025 guidance, and them "currently trending toward the upper end of the adjusted diluted EPS guidance range." While there is no avoiding the COVID-19 sales erosion and the upcoming patent cliff with ~$29B in revenues at stake, PFE has optimized its R&D efforts indeed.

STNE, CNC, CVS and PFE stand out as top value picks amid trade tensions and a murky H2 economic outlook.

Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a late-stage trial, and concerns about management's decisions on R&D spending and acquisitions have weighed on Pfizer's stock lately.

Alexandros Michailidis / iStock Editorial via Getty Images Pfizer The years after the pandemic haven't been kind to Pfizer Inc.

There are a lot of strategies investors can employ on Wall Street to grow their wealth. With thousands of publicly traded companies and more than 3,000 exchange-traded funds (ETFs) to choose from, there's bound to be one or more securities that can help you meet your investment goals.